31
Patients and E-Access: Why consider e-consenting Susan Brink, DrPH President & CEO, ConsentSolutions, Inc.

Brink Why Consider E Consenting For Clinical Trials

Embed Size (px)

DESCRIPTION

Trends that are driving the field toward e-consenting.

Citation preview

Page 1: Brink Why Consider E Consenting For Clinical Trials

Patients and E-Access:

Why consider e-consenting Susan Brink, DrPHPresident & CEO, ConsentSolutions, Inc.

Page 2: Brink Why Consider E Consenting For Clinical Trials

Marshall McLuhan

• 1964 – Understanding Media– Media as technological extensions of the body – Hot (print,radio,TV) vs Cool (smart phones,

Internet, texting, iPads, computers, uTube)– Global village (Arab Spring, Assange,

Wikipedia, crowd sourcing, social networking)

• 1967 – The Media is the Massage

“ all media works us over completely”

“ the medium is the message”

Page 3: Brink Why Consider E Consenting For Clinical Trials

HOT VERSUS COOL MEDIA

Page 4: Brink Why Consider E Consenting For Clinical Trials

TRENDS THAT MAY DRIVE CONSENT PROCESS CHANGES

• Trends – Lack of progress in literacy

– Increasing use by public of media for information – Push toward e-electronic medical records– Acceptance of web for health information – Increasing use of all types of digital signature and id– Aging of the population – Increasing use of E-consenting in other industries

Page 5: Brink Why Consider E Consenting For Clinical Trials

E-INFORMED CONSENT

Page 6: Brink Why Consider E Consenting For Clinical Trials

WHAT IS HAPPENING

• 5% of US cancer patients enrolled in trials• Enrollment rates are dropping to 59% in 2006• Retention rates are falling – 48% in 2006• Consent forms are getting longer • Informed consent: major area of FDA citations

Citations: Getz, 2008

Page 7: Brink Why Consider E Consenting For Clinical Trials

WHY CANDIDATE/PATIENT E-CONSENTING ?

•Patient Needs

•Patient Response

•Technology Reach

•Sponsor Benefit

Page 8: Brink Why Consider E Consenting For Clinical Trials

PATIENT RESPONSE COMPARED EFFECTIVENESS OF MULTIMEDIA AND PAPER-

BASED CONSENT

Number ofPeople Needed

Paper-based

Multimedia

Moekel and Brady Pharmaceutical Executive, December, 2003

Page 9: Brink Why Consider E Consenting For Clinical Trials

RESPONSE TO RANDOMIZED CROSSOVER COMPARISON

Multimedia Easy to read More accessible Interesting,

informative More effective and

exciting Faster More comprehensible

• Brink, 2006

Paper Perceived as faster

process Perceived as less

wordy Perceived as

containing more explanation

More personal

Page 10: Brink Why Consider E Consenting For Clinical Trials

PATIENT NEEDS

Comprehension?•14% of US adults are functionally illiterate (NALS 03)

•29% have marginal literacy skills (NALS 03)

•Only 13% US adults can perform complex literary tasks

Page 11: Brink Why Consider E Consenting For Clinical Trials

WHAT DO THEY NOT UNDERSTAND?

•Limited knowledge of terminology (cancer related, test related)

•Polyp, growth, lesion•Vomit (well-understood); orally (slightly over 1/3 understand); malignant and terminal (under 20%)

•Limited knowledge of their bodies and the terms used to describe location of an anatomical part (colon, bowel)

•Confuse terms (DRE and a sigmoidoscopy)

Davis et al. CA: Cancer J for Clinicians 2002:52:134-149.

Page 12: Brink Why Consider E Consenting For Clinical Trials

WHAT MIGHT HELP?

• Can be included in e-consenting – Use pictures and stories– Self-assessment – Clarify the decision•

• By clinical staff, after viewing consent – Use “teach back”

• Change at the sponsor/investigator/IRB level– Use “living room language

Davis et al. CA: Cancer J for Clinicians 2002:52:134-149.

Page 13: Brink Why Consider E Consenting For Clinical Trials

WHY NOT?

13

Page 14: Brink Why Consider E Consenting For Clinical Trials

TECHNOLOGY / REACH

•How people get information

•Transmittal of information

•Where can they get information

•World-wide Penetration

Page 15: Brink Why Consider E Consenting For Clinical Trials

HOW DO PEOPLE GET INFORMATION

» Newspaper» TV

Traditional Media» Books

» Internet New Media

» Social media sites

» friends, family, acquaintances

Page 16: Brink Why Consider E Consenting For Clinical Trials
Page 17: Brink Why Consider E Consenting For Clinical Trials

GLOBAL ICT DEVELOPMENTS 2000-2010

Page 18: Brink Why Consider E Consenting For Clinical Trials

WHO USES WHAT IN THE US?

July 2007 – US population 301,000,000

Mid-2007 ~ 239,000,000 cell phone

subscribers

73% have computers

73% are Internet users

58% of Americans 50-64 have Internet access

Over 65• 22% use computers (an increase of 47% since

2000)

Page 19: Brink Why Consider E Consenting For Clinical Trials

MULTIMEDIA VS PAPER STUDY

Study Population:

30 volunteers

50% African-American

63% over 50 years old

66% female

Over 50% had participated in a clinical trial

Page 20: Brink Why Consider E Consenting For Clinical Trials

MULTIMEDIA VS PAPER STUDY

Time Spent on 1st Consent Read Time Spent on 2nd Consent Read

0

5

10

15

20

25

30

Computer Paper

Min

ute

s

0

5

10

15

20

25

Computer After Paper Paper After Computer

Min

ute

s

Page 21: Brink Why Consider E Consenting For Clinical Trials

MULTIMEDIA VS PAPER STUDY

Computer Preference Paper Preference

Familiarity with medium

Easier to return to for review

Easier to read

Perceived as a faster process

Perceived consent as less wordy

Perceived as containing more explanation

More personal

Page 22: Brink Why Consider E Consenting For Clinical Trials

E-informed consent What is it?

A spectrum of choice

Supplements IRB approved paper-based consent

– Video explanation

– Graphics/ animation

– Text

– Audio explanation

Full consent • Presented in electronic

means

• Full IRB approved text

• Provides patient/subject specific audit trail

• Electronic signature

• Candidate/subject Education

• Amendment facility

• Voice

22

Page 23: Brink Why Consider E Consenting For Clinical Trials

E-INFORMED CONSENT WHAT IS IT?A SPECTRUM OF CHOICE

Supplements IRB approved paper-based consent

• Video explanation

• Graphics/ animation

• Text

• Audio explanation

Full consent

• Presented in electronic means

• Full IRB approved text

• Provides patient/subject specific audit trail

• Electronic signature

• Candidate/subject Education

• Amendment facility

• Voice

Page 24: Brink Why Consider E Consenting For Clinical Trials

WHAT TO CONSIDER

•ROI•Fewer the number of subjects the higher the cost per subject•Larger trials /registries

•Lower cost per subject •Time in planning

•More upfront time needed with IRB and consent •Availability of technology according to the setting/sites/population

•Wifi •Mobile devices

•Security

Page 25: Brink Why Consider E Consenting For Clinical Trials

INFORMED CONSENT IN THE INFORMATION AGE

How do we turn

information

into

Comprehension, Action and Collaboration

Page 26: Brink Why Consider E Consenting For Clinical Trials

PARTICIPANT DECISION-MAKING MODEL

INFORMATION

What do I need to know?

VALUES

How does this coincide with my personal values and

preferences?

MY DAILY LIFE

How does this fit with my life?

Informed Participant

Page 27: Brink Why Consider E Consenting For Clinical Trials

CANDIDATE KNOWLEDGE

Easily accessible education• Graphic animation Embedded Explanation graphic

/video

Page 28: Brink Why Consider E Consenting For Clinical Trials

CANDIDATE KNOWLEDGE SELF-ASSESSMENT

Page 29: Brink Why Consider E Consenting For Clinical Trials

CANDIDATE VALUES & PREFERENCES

Page 30: Brink Why Consider E Consenting For Clinical Trials

WHY CONSIDER A MEDIA BASED CONSENT?

Benefit to prospective study participants

• Understanding of trial and their role

• Presentation Preference

• Retention of information

• Engagement

Leading to more efficient recruitment and cost savings for the trial

– (Jimison et al. 1998; Verheggen & van Wijmen 1997; Fureman et al. 1997; Brady 2003; Moeckel 2005; Brink 2006 ).

Page 31: Brink Why Consider E Consenting For Clinical Trials

Susan Brink, Dr.PHPresident & CEO

ConsentSolutions, Inc 202-497-9633

[email protected]